However, given the potential for both pro- and anti-inflammatory reactions on microglial cells, therapeutic regimens using β2-AR agonists in the treatment of PD will need to be carefully developed and studied to determine the ultimate efficacy of these compounds. This evidence concerns the gene ADRB2 and Parkinson disease.